Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mabpharm Limited (2181.HK)
Taizhou, CN
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.25% | -11.24% | -11.24% | -8.14% | -25.47% | -21.00% | -21.00% | -24.04% | -66.81% | -67.36% | -67.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+143.7% ★ Q4'25: +747.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+143.6% ★ Q4'25: +148.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+6.7% Q4'25: -8.3% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+0.7% ★ Q4'25: +0.5% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+1.3% ★ Q4'25: +2.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×5.20× Q4'25: 2.61× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
82.88M
est: 112.68M (-26.4%)
|
55.92M
est: 359.95M (-84.5%)
|
258.23M
est: 385.00M (-32.9%)
|
629.37M
est: 629.37M (+0.0%)
|
129.69M
129.69M – 129.69M
-79.4% YoY
|
129.69M
129.69M – 129.69M
+0.0% YoY
|
385.00M
385.00M – 385.00M
+196.9% YoY
|
| EBITDA |
-245.46M
est: -50.99M (-381.4%)
|
-152.08M
est: -162.89M (+6.6%)
|
-67.81M
est: -243.53M (+72.2%)
|
62.91M
est: -398.10M (+115.8%)
|
-82.03M
-82.03M – -82.03M
+79.4% YoY
|
-82.03M
-82.03M – -82.03M
+0.0% YoY
|
-243.53M
-243.53M – -243.53M
-196.9% YoY
|
| EBIT |
-289.34M
est: -55.52M (-421.2%)
|
-203.63M
est: -177.34M (-14.8%)
|
-119.67M
est: -266.11M (+55.0%)
|
4.68M
est: -435.02M (+101.1%)
|
-89.64M
-89.64M – -89.64M
+79.4% YoY
|
-89.64M
-89.64M – -89.64M
+0.0% YoY
|
-266.11M
-266.11M – -266.11M
-196.9% YoY
|
| Net Income |
-291.74M
est: -279.90M (-4.2%)
|
-210.62M
est: -289.15M (+27.2%)
|
-127.95M
est: -309.27M (+58.6%)
|
55.65M
est: -250.58M (+122.2%)
|
-250.58M
-250.58M – -250.58M
+0.0% YoY
|
-308.09M
-308.09M – -308.09M
-23.0% YoY
|
-295.77M
-295.77M – -295.77M
+4.0% YoY
|
| SGA |
30.71M
est: 84.95M (-63.8%)
|
50.18M
est: 271.36M (-81.5%)
|
180.50M
est: 270.46M (-33.3%)
|
467.60M
est: 442.12M (+5.8%)
|
91.11M
91.11M – 91.11M
-79.4% YoY
|
91.11M
91.11M – 91.11M
+0.0% YoY
|
270.46M
270.46M – 270.46M
+196.9% YoY
|
| EPS |
-0.07
est: -0.07 (-4.2%)
|
-0.05
est: -0.07 (+27.1%)
|
-0.03
est: -0.07 (+58.7%)
|
0.01
est: -0.06 (+122.2%)
|
-0.06
-0.06 – -0.06
+0.0% YoY
|
-0.07
-0.07 – -0.07
-23.0% YoY
|
-0.07
-0.07 – -0.07
+4.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Wang | Chief Scientist, Chief Executive Officer & Executive Director | 1M | — |
| Yunfeng Li | Vice President, Joint Company Secretary & Executive Director | 1M | male |
| Weizhu Qian | Vice President & Executive Director | 1M | — |
| Sheng Hou | Vice President & Executive Director | 1M | — |
| Jing Tao | Vice President & Executive Director | 1M | male |
| Jing Li | Vice President | 940.7K | — |
| Yin Tsang | Joint Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2181.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
